Canaccord kept its Buy rating and cited possible 232.5% upside, but cut its target 22.2%, from $9 to $7. Those opposing views leave no clear change in Niagen Bioscience's outlook.
The kept rating and cited gain support the analyst's view of the company. The lower target points the other way, and the report offers no new sales or profit results to resolve that disagreement.
Follow Niagen Bioscience (NAGE) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for NAGE